Bacterial Vaginosis Is Linked to Higher HSV-2 Risk

BV is linked to an 85% higher risk of acquiring HSV-2

Bacterial vaginosis (BV) may affect more than odor or discharge. A 2026 systematic review and meta-analysis found that women with BV had an adjusted 85% higher rate of acquiring herpes simplex virus type 2 (HSV-2) than women without BV. That is a meaningful association, but it does not prove that treating BV prevents herpes.

The pooled estimate came from four longitudinal cohort studies of 1,906 non-pregnant, reproductive-aged cisgender women. During follow-up, 255 participants acquired HSV-2. After adjustment for measured confounders, BV was associated with an HSV-2 acquisition hazard ratio of 1.85 (95% CI, 1.36–2.52; p=0.0001). The unadjusted estimate was similar: hazard ratio 1.91 (95% CI, 1.46–2.50; p<0.0001). Both confidence intervals exclude 1.0, so the association was statistically significant in the pooled analysis. Read the Whitt et al. 2026 meta-analysis as a risk signal worth taking seriously, not as proof of a new herpes-prevention treatment.

The relative increase does not tell us an individual woman's absolute risk. That depends on HSV-2 exposure, partner infection status, condom use, local prevalence, and other factors. An 85% relative increase can matter a great deal in a high-exposure setting and much less in a low-exposure setting.

What BV changes in the vaginal environment

A Lactobacillus-dominant vaginal microbiome helps keep vaginal pH at or below 4.5, largely through lactic acid production. Lactobacilli can also produce hydrogen peroxide, bacteriocins, and other compounds that may hinder pathogens. BV describes a shift away from that ecosystem toward anaerobic bacterial overgrowth, often with a higher vaginal pH.

This makes biological sense as one route to higher STI susceptibility. The vaginal microbiome is part of the mucosal barrier, not a decorative collection of bacteria. Still, "biological plausibility" and "clinical proof" are different jobs. A 2024 review of vaginal Lactobacillus mechanisms describes several plausible antiviral defenses, including acidity, antimicrobial products, and competition with less favorable microbes. It does not establish that any one of those mechanisms prevents HSV-2 infection in real-world patients.

Species may matter. Lactobacillus crispatus produces both D- and L-lactic acid and appears to have a stronger acid-producing defensive profile than Lactobacillus iners, which produces only the L-isomer. That distinction matters for research on microbiome restoration. It does not mean that a consumer probiotic labeled "Lactobacillus" reliably recreates a L. crispatus-dominant vaginal microbiome.

The direct antiviral experiment tested HSV-1, not HSV-2

Cell-culture work adds useful, limited support. In a 2024 study of vaginal Lactobacillus supernatants, the bacterial products protected cultured cells from HSV-1 infection. That result supports the idea that vaginal Lactobacilli can produce substances with anti-herpes activity.

But the experiment used HSV-1. It did not test HSV-2, and cultured cells do not reproduce the full vaginal environment, sexual exposure, immune response, or infection risk in humans. HSV-1 and HSV-2 share features, so extrapolation is reasonable as a hypothesis. It remains an extrapolation.

The association may extend beyond herpes

Lactobacillus depletion has also been linked with a broader burden of sexually transmitted infections. A 2026 study of HIV-negative adolescent girls and young women found that Lactobacillus-deficient vaginal microbiota was associated with higher STI prevalence and co-occurrence. This was a cross-sectional study, so it measured conditions present at the same time rather than new infections over time. It cannot show whether microbiome changes raised susceptibility, infections altered the microbiome, or both occurred together.

Its value is convergence: the HSV-2 finding does not sit alone. A Lactobacillus-poor vaginal environment repeatedly appears alongside STI vulnerability. But epidemiology cannot identify a single microbial species as the cause, nor can it tell a clinician which microbiome intervention will lower a patient's risk.

Why the causal story remains unfinished

The strongest evidence here is prospective, because the four cohorts in the meta-analysis followed women for incident HSV-2 acquisition. That design is better suited to the question than a one-time snapshot. Yet prospective observational studies still cannot remove every source of confounding. Sexual networks, partner HSV-2 status, condom use, other STIs, hormonal factors, and healthcare access can all affect both BV and HSV-2 exposure or risk.

There is also evidence pointing in the other direction. A 2022 Kenyan microbiome study of women and their male sex partners reported that women with established HSV-2 had approximately 1.55-fold higher BV risk. That study was cross-sectional, so it cannot establish the sequence of events. It does, however, support a bidirectional model: BV may increase susceptibility to HSV-2, while HSV-2-related inflammation or changes in local secretions may make BV more likely.

The evidence supports an association between BV and later HSV-2 acquisition. It has not shown that clearing BV prevents HSV-2.

The meta-analysis also rests on only four eligible longitudinal studies. With so few studies, estimates of between-study differences have limited precision, and the pooled result can be sensitive to the design and quality of each cohort. The available abstract information also incompletely characterizes the cohorts' geography, baseline HSV-2 prevalence, HIV co-infection rates, age distributions, and follow-up durations. Those details can affect whether the estimate applies to a different clinic or community.

Research on outcomes after infection is thinner still. The systematic review found only two publications on HSV-2 shedding, too few for meta-analysis, and no eligible studies on reactivation or symptoms. The evidence addresses incident acquisition, not whether BV changes outbreaks, shedding frequency, or symptom severity in people who already have HSV-2.

What to do with this information

If you have recurrent or persistent BV symptoms, seek clinical evaluation and treatment. Treating symptomatic BV is standard care for its own reasons, and restoring a Lactobacillus-dominant environment is a sensible research goal. The association with HSV-2 gives that work an additional rationale: vaginal health may affect STI susceptibility as well as comfort.

Do not treat antibiotic therapy or vaginal probiotics as proven HSV-2 prophylaxis. No randomized trial or controlled prospective intervention has tested whether metronidazole, clindamycin, or Lactobacillus supplementation reduces HSV-2 acquisition. BV often recurs after antibiotics, and probiotic-driven microbiome restoration can be inconsistent. Those are practical limits, not footnotes.

For established HSV-2 prevention, use measures with direct clinical support: condoms, discussion of partner HSV-2 status, and suppressive antiviral therapy when appropriate. A 2024 phase 1 study of a 90-day tenofovir vaginal ring evaluated safety and pharmacokinetics in 49 HIV-negative participants; it did not establish HSV-2 prevention. It illustrates why a biologically appealing vaginal intervention still needs an outcome trial before it earns a prevention claim.

The practical verdict is measured. BV is associated with substantially higher HSV-2 acquisition risk, and Lactobacillus depletion offers a credible explanation. Manage BV with a clinician, protect against HSV-2 with proven methods, and regard microbiome restoration as an important unanswered prevention question rather than a substitute for those methods.